| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1567ae0f1a4843ae7bbef88fa8e1c534 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-90 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-90 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-90 |
| filingDate |
2016-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bea909ac7e2f068027c85986de6a1399
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45616fc0a196fa23d92e6122cf8f4fc5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_194b1a8d412eaaa729cd4c34c4992daf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35b5cf83bd2b195e06427e3520bf9fbc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7779fd6829fe850b1874c6b5a16e0fc7 |
| publicationDate |
2017-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017046259-A1 |
| titleOfInvention |
Improved transposon system for gene delivery |
| abstract |
Described is a transposon system comprising (a) a transposon unit containing inverted terminal repeats (ITRs) or direct terminal repeats (DTRs) that flank a sequence of interest to be inserted into the genome of a target cell; and (b) an RNA encoding a transposase capable of recognizing said ITRs and transposing said sequence of interest into said genome; wherein said RNA encoding said transposase is characterized in that it contains a combination of unmodified and modified nucleotides, wherein 5 to 50% of the uridine nucleotides and 5 to 50% of the cytidine nucleotides are respectively modified uridine nucleotides and modified cytidine nucleotides. Moreover, described is the use of a said transposon system for the ex vivo gene delivery into a target cell. Further, described is an ex vivo method for gene delivery into a target cell comprising the following steps: (a) bringing into contact the transposon system according to any one of claims 1 to 4 with a cell; (b) culturing said cell under conditions permissive to the culture of said cell. Moreover, described is also a pharmaceutical composition as well as to a kit comprising said transposon system. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022078310-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11111483-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020028533-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11278570-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11162084-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021076965-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021218000-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110997909-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3856224-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020169673-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11760983-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10227574-B2 |
| priorityDate |
2015-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |